Literature DB >> 310771

Central and peripheral antialgesic action of aspirin-like drugs.

S H Ferreira, B B Lorenzetti, F M Corrêa.   

Abstract

The peripheral and central effects of some non-steroid anti-inflammatory drugs, aspirin, indomethacin, paracetamol and phenacetin were studied by comparing their intraplantar and intracerebroventricular effects on hyperalgesia induced by carrageenin injected into the rat paw. Hyperalgesia was measured by a modification of the Randall-Selitto test. The agents tested had antialgesic effects when given by any route. Their intraventricular administration enhanced the antialgesic effect of anti-inflammatory drugs administered into the paw. Previous treatment of one paw with carrageenin reduced the oedema caused by a second injection of carrageenin in the contralateral paw. In contrast, it had no effect on the intensity of hyperalgesia but shortened the time necessary for it to reach a plateau. Administration of a prostaglandin antagonist (SC-19220) in the cerebral ventricles, in the rat paw or in both sites, significantly inhibited the hyperalgesia evoked by carrageenin. The maximal hyperalgesic effect of intraplantar injections of prostaglandin E2 could be further enhanced by its cerebroventricular administration. It was suggested that carrageenin hyperalgesia has a peripheral and a central component and that the cyclo-oxygenase inhibitors used may exert an antialgesic effect by preventing the hyperalgesia induced by a peripheral and/or central release of prostaglandins.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 310771     DOI: 10.1016/0014-2999(78)90265-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  70 in total

1.  Central, naloxone-reversible antinociception by diclofenac in the rat.

Authors:  R Björkman; J Hedner; T Hedner; M Henning
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

2.  A comparison of the hypoalgesic effect of paracetamol in slow-release and plain tablets on laser-induced pain.

Authors:  J C Nielsen; P Bjerring; L Arendt-Nielsen
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

3.  Acetaminophen as a pain enhancer during voluntary interruption of pregnancy with mifepristone and sulprostone.

Authors:  B Weber; J E Fontan
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Effects of systemic non-steroidal anti-inflammatory drugs on nociception during tail ischaemia and on reperfusion hyperalgesia in rats.

Authors:  L Gelgor; N Butkow; D Mitchell
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

Review 5.  Zomepirac: a review of its pharmacological properties and analgesic efficacy.

Authors:  P A Morley; R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-04       Impact factor: 9.546

6.  Bradykinin initiates cytokine-mediated inflammatory hyperalgesia.

Authors:  S H Ferreira; B B Lorenzetti; S Poole
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

Review 7.  Nonsteroidal anti-inflammatory drugs in perisurgical pain management. Mechanisms of action and rationale for optimum use.

Authors:  J Cashman; G McAnulty
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

8.  Activation of the arginine-nitric oxide pathway in primary sensory neurons contributes to dipyrone-induced spinal and peripheral analgesia.

Authors:  B B Lorenzetti; S H Ferreira
Journal:  Inflamm Res       Date:  1996-06       Impact factor: 4.575

9.  Inhibition of vagally mediated gastric acid secretion by activation of central prostanoid EP3 receptors in urethane-anaesthetized rats.

Authors:  K Yokotani; Y Okuma; Y Osumi
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

10.  Effects of paracetamol and aspirin on neural activity of joint mechanonociceptors in adjuvant arthritis.

Authors:  D S McQueen; A Iggo; G J Birrell; B D Grubb
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.